Background: HIV-positive patients taking antiretroviral drugs, including protease inhibitors, have shown a significant increase in the development of oral complications; these complications are a major health issue for affected patients. The effect of these drugs on oral epithelium growth and differentiation is presently unknown. In this study, we explore for the first time the effect of the HIV protease inhibitor amprenavir on gingival epithelium growth and differentiation. Methods: Organotypic (raft) cultures of gingival keratinocytes were established and the raft cultures treated with a range of amprenavir concentrations. Haematoxylin and eosin staining was performed to examine the effect of amprenavir on gingival epithelium growth and stratification. The raft cultures were also immunohistochemically analysed to determine the effect of amprenavir on the expression of key differentiation and proliferation markers, including cytokeratins, proliferating cell nuclear antigen (PCNA) and cyclin A.
Results: Amprenavir severely inhibited the growth of gingival epithelium when the drug was present throughout the growth period of the tissue. When the drug was added at day 8, amprenavir treatment altered the proliferation and differentiation of gingival keratinocytes. Expression of the cytokeratins 5, 14, 6 and 10, PCNA and cyclin A was increased; their expression pattern was also altered over time in treated rafts. Biochemically, the tissue exhibited characteristics of increased proliferation in the suprabasal layers of amprenavirtreated tissue. Conclusions: Our results suggest that amprenavir treatment deregulates the cell cycle/proliferation and differentiation pathways, resulting in abnormal epithelial repair and proliferation. Our system could be developed as a potential model for studying the effects of highly active antiretroviral therapy in vitro.
HIV infection constitutes a major health problem worldwide. Globally, 33 million people currently live with HIV, mostly in developing countries including Latin America, South-East Asia and, in particular, subSaharan Africa [1] . Oral and perioral manifestations are common in HIV-infected patients and often influence the debilitating general health status and a worse prognosis of the disease [2, 3] . The use of antiretroviral drugs, especially protease inhibitors, have markedly reduced mortality and increased the life expectancy of HIV-positive patients [4, 5] . In addition, there is a decrease in oral complications in these patients, especially oral candidiasis and oral hairy leukoplakia [6, 7] .
By contrast, other complications, such as Kaposi's sarcoma and oral apthous ulceration, have shown no significant change [6] [7] [8] . Despite having many beneficial effects on HIV-positive patients, highly active antiretroviral therapy (HAART) has been shown to have several adverse oral effects including the development of oral warts [6, 8] , xerostomia [9, 10] , erythaema multiforme [9, 10] , toxic epidermal necrolysis, lichenoid reactions [9, 11] , exfoliative cheilitis [9] , oral ulceration and paresthaesia [10, 12] .
Amprenavir (trade name Agenerase) belongs to the class of anti-HIV drugs classified as protease inhibitors. In 1999, amprenavir was approved by the US 
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Food and Drug Administration for use in adults and children with HIV infection. This drug was shown to work by inhibiting the action of the HIV protease enzyme during viral replication, thus preventing virion maturation and leading to the formation of noninfectious viral particles [13] . As with other protease inhibitors, prolonged use of amprenavir is reportedly associated with adverse orofacial effects, including oral warts, perioral paresthaesia, parotid lipomatosis, toxic epidermal necrolysis, Stevens-Johnson syndrome, xerostomia and taste disturbance [6, 9, [14] [15] [16] . Good oral health is necessary for both quality of life and adherence to drug regimens. Decreased adherence correlates with suboptimal drug levels and consequent development of drug resistance, which can compromise future therapy [17] ; therefore, any toxic side effects in the oral region owing to the long-term use of antiretroviral drugs would have a major effect on the quality of life and adherence to therapy. Cutaneous and mucosal epithelial tissues are the first line of defence from the environment. Damage to the epithelial layer allows microorganisms and toxic materials to access the underlying tissues. To help protect against damage to the epithelial lining, epithelial cells undergo a complex well-defined differentiation programme resulting in the expression of numerous structural proteins, the design of which is to maintain the integrity and function of the epithelial tissues [18] . Despite the normal structural integrity and function, damage to the epithelial tissue still occurs. This is particularly evident in the oral cavity because of its masticatory function. Regional differences in epithelial turnover show that besides the small intestine, turnover of tissues is highest in the oral cavity [19] . Normally, this allows for a rapid wound healing response when the oral epithelial lining is compromised; therefore, changes in the turnover rate of oral epithelium during treatment with HAART might affect acquisition of oral disease.
Cytokeratins are the dominant proteins expressed in the epithelium and are the fundamental markers of epithelial differentiation. The expression of specific cytokeratins appears to depend on the type of tissue, as well as on the state of differentiation or development and pathological conditions [20, 21] . Several studies have shown an alteration in the pattern of cytokeratin expression during tissue injury and the re-epithelialization process, including the expression of differentiationassociated cytokeratins as well as proliferation and wound-healing-related cytokeratins [22] [23] [24] [25] .
Protease inhibitors, including amprenavir, are associated with several adverse oral complications and the effects of this drug on the growth and differentiation of oral epithelium has yet to be evaluated. In the present study, using the organotypic (raft) tissue culture model system derived from primary gingival cells, we explore, for the first time, the effect of amprenavir on gingival epithelium growth. We also report the effects of this drug on the expression patterns of differentiation and proliferation markers.
Methods

Primary gingival keratinocytes and organotypic raft cultures
Primary gingival keratinocytes were isolated from human gingival tissue. The mixed pool of gingival tissues was obtained from patients undergoing dental surgery. Approval to collect patient samples was obtained from the Penn State University College of Medicine Institutional Review Board (IRB number 25284). The connective tissue and dermis was removed from the epithelium and discarded. The epithelial tissue was washed 3× with phosphate-buffered saline (PBS) containing 50 µg/ml gentamycin sulfate (Gibco BRL, Bethesda, MD, USA) and 1× nystatin (Sigma Chemical Co., St Louis, MO, USA). The epithelial tissue was then minced with scissors and trypsinized in a sterile glass universal containing a stir bar. The universal was placed on a magnetic stirrer at 37°C and stirred for 30 min. The supernatant was removed, 20 ml of E-media [26] supplemented with 5% fetal calf serum was added and cells were pelleted by centrifugation. The supernatant was aspirated and the cell pellet resuspended in 1 ml of 154 media (Cascade Biologics, Inc., Portland, OR, USA) and then added to a 10 cm tissue culture plate containing an additional 7 ml of 154 media. This process was repeated 3×. When cultures reached approximately 70% confluence they were split 1:3; when the plates of the first passage were >70% confluent, the cells were used for growing raft cultures.
Raft cultures were grown as previously described [26, 27] . Briefly, mouse fibroblast 3T3 J2 were trypsinized and resuspended in 10% reconstitution buffer, 10% 10× Dulbecco's modified Eagle's medium (Life Technologies, Gaithersburg, MD, USA), 2.4 µl/ml of 10 M NaOH and 80% collagen (Dickinson, Franklin Lakes, NJ, USA) to a concentration of 2.5×10 5 cells/ ml on ice. The mixture was then aliquoted into sixwell plates at 2.5 ml per well and incubated at 37°C for 2-4 h to allow solidification of the collagen matrices. A 2 ml aliquot of E-media was then added to each well to allow the matrix to equilibrate. Human gingival epithelial keratinocytes were trypsinized and resuspended at 1×10 6 cells/ml in E-media and 1 ml of cell suspension was added to each well of the sixwell plate on top of the collagen matrices from above. Epithelial cells were allowed to attach to the dermal equivalent for 2-4 h. After removal of media, the collagen matrices were lifted onto stainless steel grids at the air-liquid interface. The raft cultures were fed by diffusion from below with E-media supplemented with amprenavir. Amprenavir oral solution 15 mg/ ml (GlaxoSmithKline Research, Triangle Park, NC, USA) was purchased from the pharmacy at the Milton S Hershey Medical Center (Penn State University, Hershey, PA, USA). The required volume of drug was directly mixed in E-media. The peak concentration of a drug in the blood after its administration (C max ) of amprenavir was 7.66 µg/ml (GlaxoSmithKline). We chose to use two lower and two higher concentrations from the C max for our treatments. In the first set of experiments, the rafts were treated with amprenavir at concentrations of 2, 5, 7.66, 9 and 12 µg/ml from the first day. Control rafts were fed with E-media only. The rafts were fed every other day and harvested at days 4, 8, 12 and 16.
In the second set of experiments, the rafts were fed with E-media only for 7 days and on day 8, the rafts were treated with amprenavir at the concentrations stated above. The rafts were fed every other day and harvested at 2, 4, 6 and 8 days post-treatment.
Histochemical analyses
Raft cultures were fixed in 10% buffered formalin and embedded in paraffin; 4 µm sections were cut and stained with haematoxylin and eosin, as described previously [27] .
Immunostaining was performed with the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) [27] . Briefly, slides were baked at 55°C in a vacuum oven for 1 h. Tissue sections were dehydrated in xylene and rehydrated in alcohol gradients. Endogenous peroxidase activity was blocked by incubating the slides in 3% hydrogen peroxide. The sections were blocked for non-specific binding with 10% normal horse serum in 1% bovine serum albumin for 1 h and then blotted. Primary antibodies listed in Table 1 were applied and incubated for 60 min. After two washes in PBS, a biotin-labelled secondary antibody was applied for 30 min and then rinsed twice in PBS. A streptavidin-peroxidase complex was used to bind the biotin tag and colour visualization of the complex was achieved with 3,3′-diaminobenzidine.
Results
Establishment of primary gingival keratinocytes
Gingival epithelial cells were isolated from human gingival specimens and established in serum-free 154 culture media as described in the Methods. Gingival keratinocytes proliferated over time and demonstrated a cuboidal morphology, which is characteristic of gingival epithelial keratinocytes in the undifferentiated stage ( Figure 1A ). Cells were used at the first passage for growing raft cultures.
Effect of amprenavir on morphological differentiation and stratification of gingival keratinocytes in raft cultures
Haematoxylin and eosin staining was performed to examine the effect of amprenavir on gingival epithelial morphology and stratification in raft cultures. Among the numerous techniques used to culture gingival epithelial cells, the raft culture system has proven to accurately mimic the in vivo physiology of the gingival epidermis [28, 29] . In the first set of experiments, we applied amprenavir treatments every other day throughout the period of raft culture growth and differentiation for a total of 16 days. We treated the raft cultures with a range of amprenavir concentrations: 2, 5, 7.66, 9 and 12 µg/ml. Control rafts were fed with E-media only. The raft cultures treated with 2 and 5 µg/ ml amprenavir exhibited a significant dose-dependent growth inhibition over time compared with untreated rafts ( Figure 1B , panels i-xii); however, the growth of gingival epithelium was completely lost at 7.66, 9 and 12 µg/ml of amprenavir treatment ( Figure 1B , panels xiii-xxiv). These results suggest that amprenavir severely inhibited the growth and differentiation of gingival epithelium when the drug was present throughout the growth period. We then decided to start treating the rafts at day 8. Under normal conditions, a developing epithelium with all four strata (basal, spinosum, granulosum and corneum) can be visualized on collagen matrices on day 8. Furthermore, starting treatment on 8-day epithelium would provide the opportunity to examine the effect of this drug on developing epithelium, as present in the human oral cavity; therefore, in the second set of experiments, the rafts were treated with amprenavir at day 8 and harvested at 2, 4, 6 and 8 days post-treatment. Figure 2 demonstrates the effect of amprenavir on day 8 gingival tissues as compared with non-treated rafts. The raft cultures treated with amprenavir reflected the same morphology at 2 and 4 days post-treatment and were similar to untreated rafts (Figure 2, panels i-xii) . At 6 and 8 days post-treatment in the raft cultures treated with 2 and 5 µg/ml amprenavir, cell-cell contacts within the stratified layers appeared to be less tight compared with untreated controls and thus leading to the appearance of tissues with compromised integrity (Figure 2 , panels xiii, xiv, xv, xix, xx and xxi). Amprenavir at C max (7.66 µg/ml) and higher concentrations (9 and 12 µg/ml) interfered with the epithelium stratification and compromised gingival epithelial growth and structure over time (Figure 2 , panels xvi, xvii, xviii, xxii, xxiii and xxiv). These results indicated that amprenavir treatment on day 8 tissue changed the gingival epithelium differentiation and stratification affecting the integrity of epithelium.
Amprenavir treatment changes the expression pattern of differentiation markers in gingival epithelium treated and untreated samples, rafts were harvested and paraffin-embedded as described in the Methods. Tissue sections of treated and untreated rafts were analyzed by immunostaining with monoclonal antibodies (Table 1) . Normally, cytokeratins 5 and 14 are expressed in the basal layer of gingival stratified epithelium and have been used as proliferative cell markers [30] [31] [32] . In our study, amprenavir treatments increased and changed the expression patterns of cytokeratins 5 and 14 at 2, 4 and 6 days post-treatment when compared with untreated rafts ( Figure 3A and 3B, panels i-xviii). Cytokeratins 5 and 14 were expressed throughout the layers of treated rafts compared with untreated rafts ( Figure 3A and 3B, panels i-xviii). As cytokeratins 5 and 14 are normally expressed in the basal layer of stratified epithelium, the results of the present study suggest that amprenavir treatment altered the cell proliferation pattern and induced a more basal-like cellular environment in the upper layers that would normally be expected to have a more differentiated cellular phenotype. Amprenavir treatments severely compromised epithelium integrity at 8 days post-treatment, thereby making it difficult to observe the staining patterns (MI et al., data not shown).
The second differentiation marker studied was cytokeratin 10, which is normally expressed in low levels in the suprabasal layers of oral keratinocytes [25, 31] . Amprenavir treatment increased and changed the expression pattern of cytokeratin 10 in a dosedependent manner (Figure 4 , panels i-xviii). As compared with the control, amprenavir treatments induced the expression of cytokeratin 10 in a concentrationdependent manner at 2 and 4 days post-treatment ( Figure 4 , panels i-xii). Additionally, the cytokeratin 10 expression pattern was changed in amprenavirtreated rafts at 6 days post-treatment when compared with untreated rafts (Figure 4 , panels xiii-xviii). These results suggest that increased expression of cytokeratin 10 at early time points might be a protective response of the epithelium towards drug-induced damage.
Effects of amprenavir treatment on the expression of cytokeratin 6
Cytokeratin 6 expression is related to the wound healing process and is expressed in the suprabasal layer. Epidermal injury results in induced cytokeratin 6 expression in keratinocytes undergoing activation at the wounded edge [23, 33] . In our study, cytokeratin 6 expression was induced at 2 and 4 days post-treatment in treated rafts compared with untreated rafts ( Figure 5 , panels i-xii). However, by 6 days post-treatment, cytokeratin 6 expression in treated rafts was reduced to levels similar to those found in untreated rafts ( Figure 5 , panels xiii-xviii). Increased expression of cytokeratin 6 at 2 and 4 days post-treatment possibly suggests a wound healing response of tissue against drug-induced injury.
Amprenavir treatment-induced cell proliferation
As amprenavir treatment changed the expression patterns of the proliferation markers cytokeratins 5, 14 and 6, we decided to evaluate the effect of amprenavir on the expression of the well-known cell proliferation markers, proliferating cell nuclear antigen (PCNA) and cyclin A. PCNA is a nuclear protein that is associated with DNA polymerase δ, which is present throughout the cell cycle in proliferating cells [34] . By contrast, cyclin A regulates entry into the DNA synthesis phase (S phase) of the cell cycle, thus playing a role in the proliferation of cells [35, 36] . Immunohistochemical analysis of PCNA and cyclin A could therefore give a spatial view of cell proliferation. Under normal conditions, cell proliferation is limited to the basal layer. In our study, the PCNA and cyclin A expression in untreated rafts was limited to the basal layer at 2, 4 and 6 days post-treatment ( Figure 6A and 6B, panels i, vii and xiii); however, in amprenavir-treated rafts, PCNA and cyclin A were strongly expressed in both the basal and differentiating layers of tissue at 2 and 4 days post-treatment ( Figure 6A and 6B, panels i-xii). At 6 days post-treatment, the PCNA and cyclin A expression in amprenavir-treated rafts lessened and was lost in the rafts treated with 9 and 12 µg/ml amprenavir ( Figure 6A and 6B, panels xiv-xviii). This observation suggests that over time the tissue might become less proliferative, presumably owing to the cytostatic effects of the drug. The changed expression pattern of PCNA and cyclin A indicates the activation of the wound healing pathway against drug-induced damage. In addition, changed expression patterns of PCNA and cyclin A suggest that exposure to the drug induces a loss of cellcycle control, which could have a role in the generation of oral complications in HIV-infected patients under treatment with this drug.
Discussion
Oral complications have been reported in HIV-positive patients taking antiretroviral drugs, especially protease inhibitors; these complications are a major health issue for the affected patients. As the effect of antiretroviral drugs on oral epithelial growth and differentiation is presently unknown, we investigated for the first time the effect of the HIV protease inhibitor amprenavir on the growth of gingival epithelium and the expression patterns of key differentiation and proliferation markers.
The growth of gingival epithelium was severely inhibited when the drug was present throughout the growth period. To the best of our knowledge, no data is available on the available concentration of amprenavir in the oral cavity; however, we expect that the concentration of the drug should be at least close to or lower than its C max (7.66 µg/ml). In the present study, amprenavir, even at lower concentrations (2 and 5 µg/ml), severely affected the growth of gingival epithelium. These results support previous reports indicating that the use of antiretroviral drugs, including protease inhibitors, resulted in the development of oral complications [6, [9] [10] [11] [12] . Our observations suggest that the oral epithelium in HIV patients exposed to HAART encounters drug-induced abnormalities in the tissue's molecular and cellular biology that give rise to oral complications. To examine the effect of amprenavir on gingival keratinocyte proliferation and differentiation, we treated raft cultures at day 8. Epithelial tissues express different pairs of cytokeratin proteins depending on epithelial cell type and stage of differentiation [20, 21] . Normally, gingival stratified epithelia express the pair of cytokeratins 5 and 14 only in the proliferative basal layer [30, 32] . In the current study, amprenavir treatments increased and changed the expression patterns of cytokeratins 5 and 14 in a concentration-dependent manner over time. The expression of cytokeratin 5 and 14 appeared throughout all layers of treated rafts compared with untreated rafts. As these cytokeratins have also been shown to be enhanced in hyperproliferative situations, such as wound healing [33, 37] , induction of cytokeratins 5 and 14 in our study might be related to a transient hyperproliferation of gingival keratinocytes following amprenavir treatment. Furthermore, the presence of cytokeratins 5 and 14 in the upper layers in amprenavir-treated tissues suggests the possibility that amprenavir treatment changed pathways that regulate cytokeratin 5 and 14 expression in gingival keratinocytes.
Commitment to terminal differentiation is accompanied by a switch in keratinocyte gene expression from cytokeratins 5 and 14 to cytokeratins 1 and 10 [38] . Cytokeratin 10 is a specific terminal differentiation marker and is expressed in the suprabasal layer of keratinized epithelia. Bonan et al. [25] reported that cytokeratin 10 protects epithelium from trauma and damage. In the present study, amprenavir treatment induced the expression of cytokeratin 10 in a concentration-dependent manner at 2, 4 and 6 days post-treatment as compared with control. It is possible that enhanced synthesis of cytokeratin 10 in drugtreated gingival epithelium might be a response by the tissue to protect itself against drug-induced damage [24, 25, 39] . The enhanced level of cytokeratin 10 in drug-treated rafts might also be linked to the strong expression of cytokeratin 10 observed in oral lesions and hyperproliferative epidermis, as compared with normal epidermis [40] . Additionally, the normal balance of cytokeratin proliferation and differentiation might be disrupted upon injury and under pathological conditions [41] [42] [43] . Induction of cytokeratin 10 expression in amprenavirtreated rafts indicated the possibility that this drug caused damage to the gingival epithelium. To prove this possibility, we studied cytokeratin 6, which is expressed in response to wound injury in the suprabasal layer of stratified epithelium. In the current study, cytokeratin 6 expression was induced significantly at 2 and 4 days post-treatment in treated rafts compared with untreated rafts. Injury to stratified epithelia causes induction of cytokeratin 6 in the differentiating layers of epidermis [23, 25, 33, 44] . In addition to wound healing, cytokeratin 6 is also expressed in stratified epithelia undergoing hyperproliferation or abnormal differentiation including cancer [33, 45] . It is therefore possible that induced expression of cytokeratin 6 in amprenavir-treated rafts at 2 and 4 days post-treatment was caused by wound-healing attempts of the tissue following drug-induced tissue damage. In addition, induction of cytokeratin 6 expression in amprenavirtreated rafts suggests the possibility that exposure to the drug induces a hyperproliferative environment in the gingival tissue. Enhanced expression of PCNA and cyclin A in drug-treated rafts in our study supports these arguments. At 6 days post-treatment, amprenavir treatment specifically decreased cytokeratin 6 expression. As cytokeratin 6 expression is generally increased in tissues undergoing wound healing, decreased expression of this cytokeratin in amprenavir-treated tissues suggests that the drug interferes with wound healing pathways upon drug-induced injury. By contrast, amprenavir treatment also interfered with proliferation and differentiation programmes of gingival epithelium over time, as shown by analysis of the expression of cytokeratins 5, 14 and 10. Thus, amprenavir-mediated tissue injury, unregulated proliferation and simultaneous interference with wound healing pathways could be the reason why HIV patients undergoing treatment with protease inhibitors, including amprenavir, develop oral complications [6] [7] [8] [9] [10] [11] . Increased cell proliferation is a feature of many disorders, such as wounds, ulcers and human tumours, and the identification and use of reliable markers of proliferative activity is important in clinical practice [46, 47] . Enhancement of cytokeratin 5, 14 and 6 expression often accompanies enhanced mitotic activity in stratified epithelia [33, 48] , such that the former has often been taken as direct evidence for the latter. Because in the present study amprenavir treatment changed the expression patterns of cytokeratins 5, 14 and 6, we decided to evaluate the effect of amprenavir on the expression of the well-known cell proliferation markers PCNA and cyclin A. PCNA and cyclin A are nuclear proteins that have important roles in DNA synthesis and cell-cycle progression and cell proliferation. Both are generally detected in cell nuclei between the G1 and M phases of the cell cycle [35, 49] . These proteins are useful histochemical markers of cell proliferation because their expression and distribution correlate with cellular proliferation rates and DNA synthesis [50] . In normal conditions of cell proliferation, PCNA and cyclin A expression is limited to a few cells in the basal layer [51, 52] . In our study, PCNA and cyclin A were strongly up-regulated in the basal and suprabasal layers of the drug-treated tissue at 2 and 4 days post-treatment. Our results suggest two possibilities. Firstly, increased expression of PCNA and cyclin A indicates the activation of wound healing pathways to counteract drug-induced tissue damage. Enhanced expression of cytokeratins 10 and 6 in drugtreated rafts also supports this argument. Secondly, exposure to the drug deregulated the cell proliferation and differentiation pathways that result in abnormal proliferation and epithelial repair. This deregulation could make oral tissue more favourable for the development of the oral complications observed in HIV patients taking this drug. Furthermore, increased and altered expression patterns of cell proliferation markers, including cytokeratins 5 and 14, PCNA and cyclin A, indicate that the drug induces hyperproliferative growth conditions in the tissue, which could make it more favourable for establishing opportunistic human papillomavirus (HPV) infections. Earlier studies have shown a significant increase in the development of HPV-positive lesions in HIV patients taking HAART including protease inhibitors [6, 53, 54] .
In conclusion, we have shown that amprenavir severely inhibits the growth of gingival tissue when the drug was present throughout the growth period. This drug changed the expression pattern of cytokeratins 5, 14, 10 and 6, PCNA and cyclin A over time when the drug was added at day 8. Taken together, these results suggest that amprenavir treatment deregulates the growth, differentiation and cell cycle/proliferation pathway in human gingival tissue. Our data are supported by previous reports that the prolonged use of protease inhibitors, including amprenavir, promote several oral complications observed clinically in HIV patients. Further studies are needed to correlate these findings with detailed mechanisms of drug-induced tissue damage and subsequent wound healing.
